Advertisement

Search Results

Advertisement



Article Topics

Your search for Charlotte Bath matches 8 pages

Showing 1 - 8


leukemia

Increased Response Rate With Higher Dose of Obinutuzumab Monotherapy for Patients With Chronic Lymphocytic Leukemia

A randomized phase II study in symptomatic, untreated patients with chronic lymphocytic leukemia (CLL) found an increased overall response rate with obinutuzumab (Gazyva) at a dose of 2,000 mg vs 1,000. In addition, the “data demonstrate that obinutuzumab produces a higher response rate in...

leukemia

Patients With Relapsed or Refractory CLL Who Discontinue Ibrutinib Early Have Poor Outcomes

Most patients with relapsed or refractory chronic lymphocytic leukemia (CLL) who discontinued ibrutinib (Imbruvica) early “were difficult to treat and had poor outcomes,” according to a study of patients enrolled in four different clinical trials of ibrutinib, with or without rituximab...

leukemia

Durable Responses at 3-Year Follow-up for CLL Patients Receiving Single-Agent Ibrutinib

At a median follow-up of 3 years, ibrutinib (Imbruvica) demonstrated continued activity with durable responses that improved in quality with extended treatment of patients with chronic lymphocytic leukemia (CLL). In addition, grade 3 toxicity and adverse events leading to discontinuation diminished ...

leukemia

ASCO 2014: Ibrutinib Significantly Delays Disease Progression and Extends Survival in Relapsed CLL

Early findings from the phase III RESONATE study indicate that ibrutinib (Imbruvica) produces durable tumor responses and marked improvement in survival over standard ofatumumab (Arzerra) for patients with relapsed chronic lymphocytic leukemia (CLL). “With ibrutinib, about 80% of patients...

leukemia

Long-Term Benefit With Dasatinib After Imatinib Failure in Chronic-Phase CML

Patients with chronic myeloid leukemia (CML) in the chronic phase who are resistant or intolerant to imatinib (Gleevec) can experience long-term benefit with dasatinib (Sprycel), according to results of a randomized phase III study. The CA180-034 study also found that early molecular and...

leukemia

‘Faster and Deeper Responses’ With Dasatinib vs Imatinib in Chronic-Phase CML Patients

Dasatinib (Sprycel) resulted in “faster and deeper responses” compared to imatinib (Gleevec) among patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML), according to a 3-year follow-up of the randomized phase III DASISION (Dasatinib vs Imatinib Safety In...

leukemia

Better Leukemia-Free and Overall Survival in AML in First Remission With Cyclophosphamide Plus Busulfan vs Total-Body Irradiation

Myeloablative conditioning with cyclophosphamide combined with intravenous busulfan (Busulfex) was associated with better leukemia-free and overall survival than conditioning with cyclosphosphamide and total-body irradiation in patients with acute myeloid leukemia (AML) who were in first complete...

leukemia

Cord Blood Transplantation Benefits Some Children With Juvenile Myelomonocytic Leukemia

A retrospective analysis of 110 patients with juvenile myelomonocytic leukemia found that single-unit, unrelated donor umbilical cord blood transplantation resulted in a 5-year disease-free survival rate of 44%. “Our data document that a significant proportion of children with this disease,...

Advertisement

Advertisement



;
Advertisement